

# Programme

## Lupus Academy 10th Annual Meeting: Early Sessions (Online)

### SESSION 1: SLE TREATMENT DILEMMAS

**Tuesday 6th April 2021: 14:00–15:30 hours** CET (UTC+2 Paris, Amsterdam, Berlin)

EDT (UTC-4 New York, Montreal) 8:00 AM – 9:30 AM

CST (UTC+8 Beijing, Manila, Perth) 20:00 – 21:30 hours

| <b>Moderators: Andrea Doria (Italy), David Isenberg (UK)</b>   |                                |
|--|--------------------------------|
| Should we vaccinate all SLE patients against papillomavirus and herpes zoster?<br><b>Q&amp;A and Discussion (15 Mins)</b>        | <i>Sarfaraz Hasni (USA)</i>    |
| Hydroxychloroquine myopathy: cardiac and skeletal muscle toxicity<br><b>Q&amp;A and Discussion (15 Mins)</b>                     | <i>Murray Urowitz (Canada)</i> |
| Low dose aspirin in aPL-positive patients: Are we treating the patient or the doctor?<br><b>Q&amp;A and Discussion (15 Mins)</b> | <i>Denis Wahl (France)</i>     |

### SESSION 2: THE ROLE OF INTERFERONS IN SLE

**Friday 9th April 2021: 14:00–15:30 hours** CET (UTC+2 Paris, Amsterdam, Berlin)

EDT (UTC-4 New York, Montreal) 8:00 AM – 9:30 AM

CST (UTC+8 Beijing, Manila, Perth) 20:00 – 21:30 hours

| <b>Moderators: Zahir Amoura (France), Thomas Dörner (Germany)</b>                                 |                                |
|---|--------------------------------|
| Biology of interferons<br><b>Q&amp;A and Discussion (15 Mins)</b>                                 | <i>Mary Crow (USA)</i>         |
| How interferonopathies inform SLE pathogenesis<br><b>Q&amp;A and Discussion (15 Mins)</b>         | <i>Yanick Crow (UK)</i>        |
| Interferon inhibition and the future management of SLE<br><b>Q&amp;A and Discussion (15 Mins)</b> | <i>Eric Morand (Australia)</i> |

### SESSION 3: LESSONS LEARNED FROM OTHER DISEASES

**Monday 12th April 2021: 14:00–16:00 hours** CET (UTC+2 Paris, Amsterdam, Berlin)

EDT (UTC-4 New York, Montreal) 8:00 AM – 10:00 AM

CST (UTC+8 Beijing, Manila, Perth) 20:00 – 22:00 hours

| <b>Moderators: Eloisa Bonfá (Brazil), Ronald van Vollenhoven (Netherlands)</b>   |   |
|--|---|
| Lessons from transplantation: Multitargeted therapy for proliferative lupus nephritis<br><b>Q&amp;A and Discussion (15 Mins)</b>                                   | <i>Daniel Tak Mao Chan (Hong Kong)</i>      |
| Lessons from ITP: Treatment of refractory thrombocytopenia<br><b>Q&amp;A and Discussion (15 Mins)</b>  | <i>Sacha Zeerleder (Netherlands)</i>        |
| Lessons from scleroderma: Treatment of interstitial lung disease in SLE<br><b>Q&amp;A and Discussion (15 Mins)</b>   | <i>Oliver Distler (Switzerland)</i>         |
| Lessons from RA: RA drug development has advanced at a more rapid pace than SLE: What can we learn from our colleagues?<br><b>Q&amp;A and Discussion (15 Mins)</b> | <i>Ronald van Vollenhoven (Netherlands)</i> |

## Friday 16th April 2021

### OPENING SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:00–15:15 hours

EDT (UTC-4 New York, Montreal) 7:00 AM – 9:15 AM

CST (UTC+8 Beijing, Manila, Perth) 19:00 – 21:15 hours

|                |   |
|----------------|---|
| <b>Opening</b> | <i>Zahir Amoura (France),<br/>Richard Furie (USA)</i> |
|----------------|---|

|   |                                      |
|---|--------------------------------------|
| <b>Keynote</b>  |                                      |
| <b>Moderator: Richard Furie (USA)</b>   |                                      |
| Kidney biopsies in SLE: Too few or too many?<br><b>Q&amp;A and Discussion (15 Mins)</b> | <i>Hans-Joachim Anders (Germany)</i> |

|  |   |
|--|---|
| <b>Debate: In With the New, Out With Old? Should All Patients with Lupus Nephritis Receive New Generation Therapies in Addition to Established Standard of Care?</b> |   |
| <b>Moderator: Ronald van Vollenhoven (Netherlands)</b>   |   |
| The matter of the debate (10 mins)   | <i>Ronald van Vollenhoven (Netherlands)</i> |
| All lupus nephritis patients should be initially managed with <b>both established standard therapies and the new generation drugs</b> (20 mins + 10 mins rebuttal)   | <i>Onno Teng (Netherlands)</i>              |
| All lupus nephritis patients should be initially managed with <b>established standard therapies alone</b> (20 mins + 10 mins rebuttal)                               | <i>Dimitrios Boumpas (Greece)</i>           |
| <b>Voting, Q&amp;A and Discussion (20 Mins)</b>  | <i>All</i>                                  |

### PLENARY I: NOVEL STRATEGIES FOR OPTIMIZING OUTCOMES IN SLE

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours

EDT (UTC-4 New York, Montreal) 9:30 AM – 11:30 AM

CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:30 hours

|   |                                |
|---|--------------------------------|
| <b>Moderators: Sandra Navarra (Philippines)</b>   |                                |
| Preventing damage and reducing mortality in lupus. How are we doing?<br><b>Q&amp;A and Discussion (15 Mins)</b> | <i>Murray Urowitz (Canada)</i> |
| Strategies for minimizing corticosteroid exposure in SLE<br><b>Q&amp;A and Discussion (15 Mins)</b>             | <i>Zahir Amoura (France)</i>   |
| Targeting remission and low disease activity in SLE<br><b>Q&amp;A and Discussion (15 Mins)</b>                  | <i>Andrea Doria (Italy)</i>    |
| Lupus treatment in the next decade: The next decade is upon us<br><b>Q&amp;A and Discussion (15 Mins)</b>       | <i>Richard Furie (USA)</i>     |



# Programme

## OPENING SESSION (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 18:00–20:15 hours

EDT (UTC-4 New York, Montreal) 12:00 PM – 2:15 PM

CST (UTC+8 Beijing, Manila, Perth) 00:00 – 02:15 hours

|  |   |
|--|---|
| <b>Opening</b>   | <i>Zahir Amoura (France),<br/>Richard Furie (USA)</i> |
| <b>Keynote</b>   |   |
| <b>Moderator: Richard Furie (USA)</b>  |   |
| Kidney biopsies in SLE: Too few or too many?<br><b>Recorded Q&amp;A and Discussion (15 Mins)</b>   | <i>Hans-Joachim Anders (Germany)</i>                  |
| <b>Debate: In With the New, Out With Old? Should All Patients with Lupus Nephritis Receive New Generation Therapies in Addition to Established Standard of Care?</b> |   |
| <b>Moderator: Ronald van Vollenhoven (Netherlands)</b>   |   |
| The matter of the debate (10 mins)   | <i>Ronald van Vollenhoven<br/>(Netherlands)</i>       |
| All lupus nephritis patients should be initially managed with <b>both established standard therapies and the new generation drugs</b> (20 mins + 10 mins rebuttal)   | <i>Onno Teng (Netherlands)</i>                        |
| All lupus nephritis patients should be initially managed with <b>established standard therapies alone</b> (20 mins + 10 mins rebuttal)                               | <i>Dimitrios Boumpas (Greece)</i>                     |
| <b>Recorded Voting, Q&amp;A and Discussion (20 Mins)</b>   | <i>All</i>  |

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

**Saturday 17th April 2021**

## PLENARY I: NOVEL STRATEGIES FOR OPTIMIZING OUTCOMES IN SLE (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 07:00–09:00 hours

EDT (UTC-4 New York, Montreal) 1:00 AM – 3:00 AM

CST (UTC+8 Beijing, Manila, Perth) 13:00 – 15:00 hours

| <b>Moderators: Sandra Navarra (Philippines)</b>  |                               |
|--|-------------------------------|
| Preventing damage and reducing mortality in lupus. How are we doing?<br><b>Recorded Q&amp;A and Discussion (15 Mins)</b> | <i>Murray Urowiz (Canada)</i> |
| Strategies for minimizing corticosteroid exposure in SLE<br><b>Recorded Q&amp;A and Discussion (15 Mins)</b>             | <i>Zahir Amoura (France)</i>  |
| Targeting remission and low disease activity in SLE<br><b>Recorded Q&amp;A and Discussion (15 Mins)</b>                  | <i>Andrea Doria (Italy)</i>   |
| Lupus treatment in the next decade: The next decade is upon us<br><b>Recorded Q&amp;A and Discussion (15 Mins)</b>       | <i>Richard Furie (USA)</i>    |

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

## CASE STUDY INTERACTIVE WORKSHOPS

CET (UTC+2 Paris, Amsterdam, Berlin) 09:00–10:30 hours

EDT (UTC-4 New York, Montreal) 3:00 AM – 4:30 AM

CST (UTC+8 Beijing, Manila, Perth) 15:00 – 16:30 hours

| <b>Moderator/Facilitator: Andrea Doria (Italy)</b>         |   |
|--|---|
| Cutaneous lupus  | <i>Bernardo Pons-Estel (Argentina), Annegret Kuhn (Germany)</i> |
| <b>Moderator/Facilitator: Sandra Navarra (Philippines)</b> |   |
| Lupus nephritis  | <i>Liz Lightstone (UK), Sandra Navarra (Philippines)</i>        |
| <b>Moderator/Facilitator: David Isenberg (UK)</b>          |   |
| Paediatric SLE   | <i>Alexandre Belot (France), Rolando Cimaz (Italy)</i>          |
| <b>Moderator/Facilitator: Ricard Cervera (Spain)</b>       |   |
| Neuropsychiatric SLE                                       | <i>Ricard Cervera (Spain), Thomas Huizinga (NL)</i>             |
| <b>Moderator/Facilitator: Eloisa Bonfá (Brazil)</b>        |   |
| Reproductive health in SLE                                 | <i>Lisa Sammaritano (USA), Rebecca Fischer-Betz (Germany)</i>   |

## HOT TOPICS: THE ROLE OF COMPLEMENT IN SLE

CET (UTC+2 Paris, Amsterdam, Berlin) 11:00–13:00

EDT (UTC-4 New York, Montreal) 5:00 AM – 7:00 AM

CST (UTC+8 Beijing, Manila, Perth) 17:00 – 19:00 hours

| <b>Moderators: Thomas Dörner (Germany), David Isenberg (UK)</b>  |                               |
|--|-------------------------------|
| Complement in SLE<br><b>Q&amp;A and Discussion (15 Mins)</b>   | <i>John Atkinson (USA)</i>    |
| The role of complement and complement inhibition in APS pregnancy<br><b>Q&amp;A and Discussion (15 Mins)</b> | <i>Jane Salmon (USA)</i>      |
| The interface of the complement and coagulation pathways<br><b>Q&amp;A and Discussion (15 Mins)</b>          | <i>Edward Conway (Canada)</i> |
| Lessons learned from complement inhibition in ANCA vasculitis<br><b>Q&amp;A and Discussion (15 Mins)</b>     | <i>David Jayne (UK)</i>       |

# Programme

## PRIME TIME SESSION

CET (UTC+2 Paris, Amsterdam, Berlin) 13:30–15:30 hours

EDT (UTC-4 New York, Montreal) 7:30 AM – 09:30 AM

CST (UTC+8 Beijing, Manila, Perth) 19:30 – 21:30 hours

### Hot Topics: Highlighting Accomplishments in Lupus Research

#### Moderators: Murray Urowitz (Canada), David Isenberg (UK)

|  |                         |
|--|-------------------------|
| Translational insights into the pathogenesis transforming SLE treatment<br><b>Q&amp;A and Discussion (15 Mins)</b> | Thomas Dörner (Germany) |
|--|-------------------------|

|  |                  |
|--|------------------|
| Clinical science highlights that are transforming treatment<br><b>Q&amp;A and Discussion (15 Mins)</b> | Bevra Hahn (USA) |
|--|------------------|

### Thieves' Market

#### Moderators: Richard Furie (USA), Eloisa Bonfá (Brazil)

|   |                            |
|---|----------------------------|
| Case in practice: Neither arms NOR legs were feeling well<br><b>Q&amp;A (10 Mins)</b> | Eduardo Dourado (Portugal) |
|---|----------------------------|

|  |                       |
|--|-----------------------|
| Case in practice: Born together, best friends together<br><b>Q&amp;A (10 Mins)</b> | Rinat Raupov (Russia) |
|--|-----------------------|

|  |                           |
|--|---------------------------|
| Case in practice: A short hi-storiform of time in clinic<br><b>Q&amp;A (10 Mins)</b> | Saskia Rowson (Australia) |
|--|---------------------------|

### Voting and Panel Discussion

## CASE STUDY INTERACTIVE WORKSHOPS

CET (UTC+2 Paris, Amsterdam, Berlin) 16:00–17:30 hours

EDT (UTC-4 New York, Montreal) 10:00 AM – 11:30 PM

CST (UTC+8 Beijing, Manila, Perth) 22:00 – 23:30 hours

#### Moderator/Facilitator: Andrea Doria (Italy)

|                 |  |
|-----------------|--|
| Cutaneous lupus | Bernardo Pons-Estel (Argentina), Annegret Kuhn (Germany) |
|-----------------|--|

#### Moderator/Facilitator: Sandra Navarra (Philippines)

|                 |   |
|-----------------|---|
| Lupus nephritis | Liz Lightstone (UK), Sandra Navarra (Philippines) |
|-----------------|---|

#### Moderator/Facilitator: David Isenberg (UK)

|                |   |
|----------------|---|
| Paediatric SLE | Alexandre Belot (France), Rolando Cimaz (Italy) |
|----------------|---|

#### Moderator/Facilitator: Murray Urowitz (Canada)

|                      |  |
|----------------------|--|
| Neuropsychiatric SLE | Ricard Cervera (Spain), Thomas Huizinga (NL) |
|----------------------|--|

#### Moderator/Facilitator: Eloisa Bonfá (Brazil)

|                            |  |
|----------------------------|--|
| Reproductive health in SLE | Lisa Sammaritano (USA), Rebecca Fischer-Betz (Germany) |
|----------------------------|--|

### Close

## HOT TOPICS: THE ROLE OF COMPLEMENT IN SLE (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 18:30–20:30

EDT (UTC-4 New York, Montreal) 12:30 PM – 2:30 PM

CST (UTC+8 Beijing, Manila, Perth) 00:30 – 14:30 hours

#### Moderators: Thomas Dörner (Germany), David Isenberg (UK)

|  |                     |
|--|---------------------|
| Complement in SLE<br><b>Q&amp;A and Discussion (15 Mins)</b> | John Atkinson (USA) |
|--|---------------------|

|  |                   |
|--|-------------------|
| The role of complement and complement inhibition in APS pregnancy<br><b>Q&amp;A and Discussion (15 Mins)</b> | Jane Salmon (USA) |
|--|-------------------|

|   |                        |
|---|------------------------|
| The interface of the complement and coagulation pathways<br><b>Q&amp;A and Discussion (15 Mins)</b> | Edward Conway (Canada) |
|---|------------------------|

|  |                  |
|--|------------------|
| Lessons learned from complement inhibition in ANCA vasculitis<br><b>Q&amp;A and Discussion (15 Mins)</b> | David Jayne (UK) |
|--|------------------|

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.

## Sunday 18th April 2021

### PLENARY II: TREATMENT CHALLENGES

CET (UTC+2 Paris, Amsterdam, Berlin) 09:00–11:00 hours

EDT (UTC-4 New York, Montreal) 03:00 AM – 5:00 AM

CST (UTC+8 Beijing, Manila, Perth) 15:00 – 17:00 hours

| <b>Moderators: Zahir Amoura (France)</b>  |  |
|---|--|
| Treatment of CAPS: Which drugs and in which order?<br><b>Q&amp;A and Discussion (15 Mins)</b>   | <i>Marc Pineton de Chambrun (France)</i> |
| Refractory cutaneous lupus: Use of thalidomide or lenalidomide for refractory lupus skin disease<br><b>Q&amp;A and Discussion (15 Mins)</b> | <i>François Chasset (France)</i>         |
| Osteonecrosis: Prevention and treatment<br><b>Q&amp;A and Discussion (15 Mins)</b>  | <i>Bernardo Pons Estel (Argentina)</i>   |
| Alveolar hemorrhage<br><b>Q&amp;A and Discussion (15 Mins)</b>  | <i>Ricard Cervera (Spain)</i>            |

### POSTER SESSION\*: PRESENTATIONS

CET (UTC+2) Paris, Amsterdam, Berlin) 11:30–12:30 hours

EDT (UTC-4 New York, Montreal) 05:30 AM – 06:30 AM

CST (UTC+8 Beijing, Manila, Perth) 17:30 – 18:30 hours

| <b>Moderators: Andrea Doria (Italy), Ronald van Vollenhoven (Netherlands)</b>   |                                    |
|---|------------------------------------|
| Incorporation of Banff classification in lupus histopathology assessment emphasizes the importance of tubulointerstitial changes<br><b>Q&amp;A (5 Mins)</b>                 | <i>Peter Korsten (Germany)</i>     |
| ISG15 deficiency underlie monogenic lupus with inflammatory myositis<br><b>Q&amp;A (5 Mins)</b>   | <i>Lujayn Akbar (Saudi Arabia)</i> |
| Immunophenotype of systemic lupus erythematosus and Sjögren's syndrome patients identified two endotypes with potential therapeutic implications<br><b>Q&amp;A (5 Mins)</b> | <i>Lucia Martin-Gutierrez (UK)</i> |
| Comparison of different definitions of remission in children with lupus nephritis<br><b>Q&amp;A (5 Mins)</b>  | <i>Chiara De Mutis (Italy)</i>     |
| Multi-omic analysis identifies dyslipidaemia in juvenile-SLE patients associated with disease activity, inflammation and atherosclerosis<br><b>Q&amp;A (5 Mins)</b>         | <i>George Robinson (UK)</i>        |

\*More Posters Available Online

### MEETING HIGHLIGHTS

CET (UTC+2) Paris, Amsterdam, Berlin) 13:00–14:00 hours

EDT (UTC-4 New York, Montreal) 07:00 AM – 08:00 AM

CST (UTC+8 Beijing, Manila, Perth) 19:00 – 20:00 hours

| <b>Moderators: Zahir Amoura (France), Richard Furie (USA)</b> |   |
|---|---|
| Meeting Highlights  | <i>Eloisa Bonfá (Brazil), David Isenberg (UK), Richard Furie (USA), Zahir Amoura (France)</i> |
| Questions and Answers (Live)                                  | <i>Steering Committee</i>   |
| <b>Close</b>  | <i>Zahir Amoura (France), Richard Furie (USA)</i>   |



# Programme

## MEET THE EDITOR

CET (UTC+2) Paris, Amsterdam, Berlin) 14:15 – 15:00 hours

EDT (UTC-4 New York, Montreal) 8:15 AM – 9:00 AM

CST (UTC+8 Beijing, Manila, Perth) 20:15 – 21:00 hours

| <b>Moderator: Ronald van Vollenhoven (Netherlands)</b>                       |   |
|--|---|
| Introduction: What is happening in the world of publishing?                  | <i>Ronald van Vollenhoven<br/>(Netherlands)</i> |
| Workshop: How do I get my manuscript published—in the best possible journal? |   |
| Tips for reviewers: make it work for the authors and yourself                |   |

## PLENARY II: TREATMENT CHALLENGES (PRE-RECORDED)\*

CET (UTC+2 Paris, Amsterdam, Berlin) 15:30–17:30 hours

EDT (UTC-4 New York, Montreal) 9:30 AM – 11:30 AM

CST (UTC+8 Beijing, Manila, Perth) 21:30 – 23:30 hours

| <b>Moderators: Zahir Amoura (France)</b>  |  |
|---|--|
| Treatment of CAPS: Which drugs and in which order?<br><b>Q&amp;A and Discussion (15 Mins)</b>   | <i>Marc Pineton de Chambrun<br/>(France)</i> |
| Refractory cutaneous lupus: Use of thalidomide or lenalidomide for refractory lupus skin disease<br><b>Q&amp;A and Discussion (15 Mins)</b> | <i>François Chasset (France)</i>             |
| Osteonecrosis: Prevention and treatment<br><b>Q&amp;A and Discussion (15 Mins)</b>  | <i>Bernardo Pons Estel (Argentina)</i>       |
| Alveolar hemorrhage<br><b>Q&amp;A and Discussion (15 Mins)</b>  | <i>Ricard Cervera (Spain)</i>                |

\*Please note that this session (presentation and discussion) is pre-recorded and there will not be an opportunity to participate in discussion.